The natural history of asymptomatic positron emission tomography: positive giant cell arteritis after a case of self-limiting polymyalgia rheumatica

2012 ◽  
Vol 22 (6) ◽  
pp. 942-946 ◽  
Author(s):  
Hiroyuki Yamashita ◽  
Mariko Inoue ◽  
Yuko Takahashi ◽  
Toshikazu Kano ◽  
Akio Mimori
Keyword(s):  
Positron Emission Tomography ◽  
Natural History ◽  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Polymyalgia Rheumatica ◽  
Emission Tomography ◽  
Positron Emission ◽  
History Of

scholarly journals High frequency of capsular knee involvement in polymyalgia rheumatica/giant cell arteritis patients studied by positron emission tomography

Rheumatology ◽  
2013 ◽  
Vol 52 (10) ◽  
pp. 1865-1872 ◽  
Author(s):  
Marco A. Cimmino ◽  
Dario Camellino ◽  
Francesco Paparo ◽  
Silvia Morbelli ◽  
Michela Massollo ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Polymyalgia Rheumatica ◽  
High Frequency ◽  
Emission Tomography ◽  
Positron Emission

scholarly journals Polymyalgia rheumatica in the 2018–2020 guidelines. Part II: diagnosis of vasculitis

2021 ◽  
Vol 11 (1) ◽  
pp. 1-16
Author(s):  
О.H. Puzanova ◽  
А.А. Lyzikov
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Nuclear Medicine ◽  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Computed Tomography Angiography ◽  
Polymyalgia Rheumatica ◽  
Aortic Aneurysms ◽  
Emission Tomography ◽  
Positron Emission

The issue of improved diagnosis of both rheumatic diseases of the elderly and aortic diseases does not lose its relevance. In terms of aortic aneurysms, dissection and ruptures and their attended pathogenesis, both inflammation and structural wall damages may be detected with imaging methods whose role is vital. A number of international guidelines deal with the ma­nagement of polymyalgia rheumatica, giant cell arteritis, or aortic aneurysms. Aortitis is associated with up to 40 % of polymyalgia rheumatica’s cases. The clinical suspicion of aortitis is based on the detection of blood pressure and pulse asymmetry, aortic regurgitation murmur, vascular bruits, as well as persistent polymyalgia rheumatica or inflammatory dorsalgia, pelvis or leg pain. In 2020, the positron emission tomography/computed tomography’s use is approved by the Italian Society for Rheumatology for the diagnosis of vasculitis attended by polymyalgia rheumatica at the secon­dary healthcare level and by the European Headache Federation for the diagnosis of large vessel giant cell arteritis in the neurological practice. A review of the guideline by the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the American Society of Nuclear Cardiology (2018) was performed in terms of po­sitron emission tomography with fluorodesoxyglucose combined with computed tomography (angiography) imaging in large vessel vasculitis and polymyalgia rheumatica. It is further compared with the clinical guidelines, other guidelines by the societies of nuclear medicine and new scientific data. Both procedure and patient’s preparation for examination are decribed. The criteria for assessing vasculitis proposed for either clinical practice or cli­nical studies are consi­dered, as well as the factors influencing the test results and their interpretation (such as atherosclerosis, diabetes, age, body mass index, glucemia’s and acute phase markers’ levels). The guideline substantiates the benefit of both positron emission tomography’s use and its combination with computed tomography to detect extracranial vasculitis, as well as the va­lue of performing computed tomography-angiography at different stages of the disease. There is a need to strengthen evidence on both standard time of fluorodesoxyglucose exposure and the benefit of combining positron emission tomography with computed tomography-angiography, in particular for detection of vasculitis relapses. Finding a consensus for early test’s performing is nee­ded, as well as its score standardization, ensuring reimbursement and implementation of new imaging techniques for the cranial vessels. In the future, the evidence-based approach to managing vasculitis will be supplemented by teranostics.

scholarly journals Polymyalgia rheumatica in the 2018–2020 clinical guidelines. Part I. At-risk groups, adjuvant therapy

2020 ◽  
Vol 10 (4) ◽  
pp. 161-173
Author(s):  
О.G. Puzanovа
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Nuclear Medicine ◽  
Adjuvant Therapy ◽  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Polymyalgia Rheumatica ◽  
Emission Tomography ◽  
Evidence Based ◽  
Positron Emission

At the beginning of the Healthy Ageing Decade, a number of guidelines were published describing management of the rheumatic diseases of the elderly. The aim of the paper is to cha­racterize and discuss the Italian Society of Rheumatology’s guideline for polymyalgia rheumatica (2020) and the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the American Society of Nuclear Cardio­logy’s (2018) recommendation for positron-emission tomography/computed tomography imaging to diagnose the large vessel vasculitis and polymyalgia rheumatica. The following methods were used: original texts of recommedations, their content and methodology behind the development of both guidelines were studied by means of information analysis and compared with the recommendations for the management of polymyalgia rheumatica and giant cell arteritis elaborated in 2018–2020 by the European League Against Rheumatism, American College of Rheumatology; the German, Austrian, Swiss and British rheumatological societies; the European Headache Federation and their references. We’ve established the priority of consensus approach for the development of modern guidelines for polymyalgia rheumatica. The specific feature of the Italian guideline’s development is the search for prototypes restric­ted to the two evidence-based medicine databases and the grey li­terature as well as selection of three international guidelines for ­adaptation, one of them elaborated by the societies for nuclear me­dicine. The following issues were updated: the patient management in primary care (whose algorithm is proposed), including the conserted clinical decision-making and alertness to the giant cell arteritis. Out of the first-line therapy tools, only the initial doses of glucocorticoids are evidence-based, and their reduction is allowed as an alternating regimen. The ineffectiveness of hydroxichloroquine use is justified, while both azathioprine and alternative medical drugs are not subject to discussion. It is necessary to identify the risk factors for vasculitis and its relapses, longterm glucocorticoid use and their side effects. For the first time, the use of positron-emission tomography/computed tomography is recommended for detecting of vasculitis. The recommendation for adjuvant therapy with methotrexate and abstaining from the biologic agents is found the most evidence-based, strongest and consistent; referral to a rheumatologist being the least agreed-on position. Conclusion. Solving such an urgent healthcare problem as improving the quality of polymyalgia rheumatic management suggests the medical standards being raised on the most clinically important issues, the importance of at-risk patient identification and referral to rheumatologists and ophthalmologists, and consideration of the methotrexate’s benefits.

scholarly journals FDG positron emission tomography of giant cell arteritis with polymyalgia rheumatica

2015 ◽  
Vol 2015 (mar11 1) ◽  
pp. bcr2014206887-bcr2014206887
Author(s):  
K. Shikino ◽  
M. Ikusaka ◽  
F. Shimada
Keyword(s):  
Positron Emission Tomography ◽  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Polymyalgia Rheumatica ◽  
Emission Tomography ◽  
Positron Emission
Sign in / Sign up

Export Citation Format

Share Document